Posts Tagged ‘policy’

Navigating the patentability of stem cells

This is a guest post from the BiotechBlog Intern, Fintan Burke. Fintan is a student at the School of Biotechnology at Dublin City University. Do you have a response to Fintan’s post? Respond in the comments section below. In Europe the 1998 EU Biotechnology directive (98/44/EC) states that Totipotent stem cells (stem cells that develop […]

Featured in Fortune article on Drug Patent Challenges

Fortune magazine recently published an article on the growing trend of generic companies challenging pharmaceutical drug patents. I enjoyed working with the writer to help layout the industry landscape, and share my knowledge of drug patents and trends from It’s a good read, and it does an excellent job of laying out the legal, […]

Synthetic Biology: What's the Agenda?

The Center for Policy on Emerging Technologies, where I am on the board of directors, is hosting an Emerging Technologies Roundtable: August 13, 2010 – “Synthetic Biology: What’s the Agenda?” Synthetic biology has hit the headlines yet again. The J. Craig Venter Institute’s recent dramatic announcement led to a replay of President Clinton’s urgent request […]

The impact of the global financial crisis on biotechnology development

My most recent editorial in the Journal of Commercial Biotechnology, “The impact of the global financial crisis on biotechnology development,” examines the response of governments around the world to their investments in biotechnology and healthcare innovation. It is a theme that I also raised in the Scientific American WorldVIEW. The bottom line is: despite economic […]